139 related articles for article (PubMed ID: 37868796)
1. Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration.
Kikuchi Y; Kawczynski MG; Anegondi N; Neubert A; Dai J; Ferrara D; Quezada-Ruiz C
Ophthalmol Sci; 2024; 4(2):100385. PubMed ID: 37868796
[TBL] [Abstract][Full Text] [Related]
2. Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration.
Maunz A; Barras L; Kawczynski MG; Dai J; Lee AY; Spaide RF; Sahni J; Ferrara D
Ophthalmol Sci; 2023 Dec; 3(4):100319. PubMed ID: 37304043
[TBL] [Abstract][Full Text] [Related]
3. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.
Schmidt-Erfurth U; Bogunovic H; Sadeghipour A; Schlegl T; Langs G; Gerendas BS; Osborne A; Waldstein SM
Ophthalmol Retina; 2018 Jan; 2(1):24-30. PubMed ID: 31047298
[TBL] [Abstract][Full Text] [Related]
4. Hyperreflective Material Boundary Remodeling in Neovascular Age-Related Macular Degeneration: A Post Hoc Analysis of the AVENUE Trial.
Yu S; Bachmeier I; Hernandez-Sanchez J; Garcia Armendariz B; Ebneter A; Pauleikhoff D; Chakravarthy U; Fauser S
Ophthalmol Retina; 2023 Nov; 7(11):990-998. PubMed ID: 37422192
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
[TBL] [Abstract][Full Text] [Related]
7. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
[TBL] [Abstract][Full Text] [Related]
8. Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration from a Phase III Clinical Trial.
Yordi S; Cakir Y; Cetin H; Talcott KE; Srivastava SK; Hu J; Ehlers JP
Ophthalmol Retina; 2024 Feb; ():. PubMed ID: 38360182
[TBL] [Abstract][Full Text] [Related]
9. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
Khanani AM; Aziz AA; Khan H; Gupta A; Mojumder O; Saulebayeva A; Abbey AM; Almeida DRP; Avery RL; Banda HK; Barakat MR; Bhandari R; Chang EY; Haug SJ; London NJS; Mein L; Sheth VS; Wolfe JD; Singer MA; Danzig CJ
Eye (Lond); 2023 Dec; 37(17):3574-3581. PubMed ID: 37173428
[TBL] [Abstract][Full Text] [Related]
10. Development of Deep Learning Models to Predict Best-Corrected Visual Acuity from Optical Coherence Tomography.
Kawczynski MG; Bengtsson T; Dai J; Hopkins JJ; Gao SS; Willis JR
Transl Vis Sci Technol; 2020 Sep; 9(2):51. PubMed ID: 32974088
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
[TBL] [Abstract][Full Text] [Related]
12. BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale.
Hattenbach LO; Abreu F; Arrisi P; Basu K; Danzig CJ; Guymer R; Haskova Z; Heier JS; Kotecha A; Liu Y; Loewenstein A; Seres A; Willis JR; Wykoff CC; Paris LP
Ophthalmol Sci; 2023 Sep; 3(3):100302. PubMed ID: 37810589
[TBL] [Abstract][Full Text] [Related]
13. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
Ophthalmology; 2024 Feb; ():. PubMed ID: 38382813
[TBL] [Abstract][Full Text] [Related]
14. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice.
Guymer R; Bailey C; Chaikitmongkol V; Chakravarthy U; Chaudhary V; Finger RP; Gallego-Pinazo R; Chuan AKH; Ishida S; Lövestam-Adrian M; Parravano M; Luna Pinto JD; Schmitz-Valckenberg S; Sheth V; Souied EH; Chi GC; Gilberg F; Glittenberg C; Scheidl S; Bengus M
Ophthalmol Sci; 2024; 4(3):100442. PubMed ID: 38304609
[TBL] [Abstract][Full Text] [Related]
15. Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.
Sodhi SK; Pereira A; Oakley JD; Golding J; Trimboli C; Russakoff DB; Choudhry N
PLoS One; 2022; 17(2):e0262111. PubMed ID: 35157713
[TBL] [Abstract][Full Text] [Related]
16. Artificial Intelligence-Based Quantification of Central Macular Fluid Volume and VA Prediction for Diabetic Macular Edema Using OCT Images.
Ye X; Gao K; He S; Zhong X; Shen Y; Wang Y; Shao H; Shen L
Ophthalmol Ther; 2023 Oct; 12(5):2441-2452. PubMed ID: 37318706
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
[TBL] [Abstract][Full Text] [Related]
18. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
19. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis.
Ciulla TA; Kapik B; Grewal DS; Ip MS
Ophthalmol Retina; 2021 Jul; 5(7):633-647. PubMed ID: 33130256
[TBL] [Abstract][Full Text] [Related]
20. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
Staurenghi G; Cozzi M; Sadda S; Hill L; Gune S
Ophthalmol Retina; 2023 Apr; 7(4):300-306. PubMed ID: 36372347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
